Precision Oncology as a Model for Bridging the “Valley of Death”

Posted by: Kristein King -

A persistent challenge in anti-cancer drug development remains translation from animal studies to human clinical trials. A shocking 57% of late-stage oncology trials fail due to inadequate efficacy. These failures amount to billions of dollars in...

Read More

Orthotopic PDX: The Gold Standard in Precision Oncology

Posted by: Kristein King -

On December 15th, 2020, Dr. Jonathan Nakashima, PhD, CSO of Certis Oncology, joined Taconic Biosciences to present a comprehensive overview of O-PDX testing.  O-PDX is a technique which uses in vivo pharmacology testing in personalized mouse models,...

Read More